康方生物今日盘中股价大跌9.65%，引发了市场的广泛关注。
消息面上，此次股价下跌主要受其海外合作伙伴Summit Therapeutics的负面消息拖累。双方合作推进的依沃西单抗一线非小细胞肺癌全球三期临床试验，在中期无进展生存期分析后宣布研究继续进行。市场将此解读为数据未达到即时积极信号，导致Summit Therapeutics股价此前大跌25%。康方生物在节后首个交易日受此情绪传导影响，股价出现明显补跌。
根据公司此前披露的财务数据，康方生物全年总收入同比增长显著，但年度净亏损规模仍较大。在今日的生物科技板块中，同行业公司股价表现出现分化。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.